Laulimalide

Drug Profile

Laulimalide

Latest Information Update: 17 Feb 2006

Price : $50

At a glance

  • Originator Utah State University
  • Developer University of Hawaii; Utah State University
  • Class Antineoplastics; Lactones
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Feb 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 31 Dec 2001 This agent is still in active development
  • 14 May 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top